Skip to main content
Erschienen in: Tumor Biology 2/2015

01.02.2015 | Research Article

Preliminary mechanism on the methylation modification of Dkk-1 and Dkk-3 in hepatocellular carcinoma

verfasst von: Libo Liang, He He, Ruixue Lv, Mei Zhang, Henjian Huang, Zhenmei An, Shuangqing Li

Erschienen in: Tumor Biology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Wnt/β-catenin signaling pathway, having a crucial role in regulating diverse cellular processes, can be a new therapeutic target in cancer. To investigate the role of Dkk-1 (Dickkopf-1) and Dkk-3 in tumors and cirrhoses of the liver tissue in hepatocellular carcinoma (HCC), tissues from 38 patients with HCC resections including 5 patients who underwent hemangioma surgery of adjacent tumor tissues at the same time were obtained. Tissues were divided into three groups (nonfibrosis, cirrhosis, and carcinoma) through hematoxylin-eosin (HE) staining. Methylation-specific polymerase chain reaction (PCR) (MSP) measured the methylation status, and reverse transcription-PCR tested the messenger RNA (mRNA) levels, and immunohistochemical analysis provided levels of protein expression. The methylation detection rate of Dkk-1 and Dkk-3 was the highest (P < 0.05) and the mRNA levels of Dkk-1 and Dkk-3 were the lowest (P < 0.05) in the carcinoma tissues. The mRNA levels of β-catenin were significantly higher in the carcinoma tissue than the other tissues (P < 0.05). The expression of Dkk-1 and Dkk-3 was significantly higher in the carcinoma tissues than the other tissues (P < 0.05); but the β-catenin expression was the highest (P < 0.05). Compared with the control, the mRNA levels of β-catenin in the Dkk-1 and Dkk-3 silencing cells increased 5.34 (P < 0.05) and 3.5 times (P > 0.05). After the interference of 5-aza-2′-deoxycytidine, the mRNA levels of Dkk-1 and Dkk-3 significantly increased 58.9 and 59.3 times (P < 0.0001), and the mRNA levels of β-catenin decreased 6.02 times (P < 0.05). In the process of HCC, the abnormal activity of Wnt/β-catenin signaling may be associated with the methylation of Dkk-1 and Dkk-3.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Zurück zum Zitat Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21:59–69.CrossRefPubMed Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21:59–69.CrossRefPubMed
3.
Zurück zum Zitat Anastas JN, Moon RT. Wnt signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMed Anastas JN, Moon RT. Wnt signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMed
4.
Zurück zum Zitat Ye SL, Chen RX. [comments on management of hepatocellular carcinoma: An update]. Zhonghua gan zang bing za zhi, Zhonghua ganzangbing zazhi, Chin J Hepatol. 2011;19:251–3. Ye SL, Chen RX. [comments on management of hepatocellular carcinoma: An update]. Zhonghua gan zang bing za zhi, Zhonghua ganzangbing zazhi, Chin J Hepatol. 2011;19:251–3.
5.
Zurück zum Zitat Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Canc Offic J Int Gastric Canc Assoc Japan Gastric Canc Assoc. 2014. doi:10.1007/s10120-014-0348-0. Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Canc Offic J Int Gastric Canc Assoc Japan Gastric Canc Assoc. 2014. doi:10.​1007/​s10120-014-0348-0.
6.
Zurück zum Zitat Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum dkk1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.CrossRefPubMed Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum dkk1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.CrossRefPubMed
7.
Zurück zum Zitat Shi J, Keller J, Zhang J, Keller E. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of wnts and the dickkopf family of wnt inhibitors. J Hepato Carcinom. 2014;1:1–7. Shi J, Keller J, Zhang J, Keller E. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of wnts and the dickkopf family of wnt inhibitors. J Hepato Carcinom. 2014;1:1–7.
8.
Zurück zum Zitat Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of dkk1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50:948–57.CrossRefPubMed Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of dkk1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50:948–57.CrossRefPubMed
10.
Zurück zum Zitat Veeck J, Dahl E. Targeting the wnt pathway in cancer: the emerging role of dickkopf-3. Biochim Biophys Acta. 1825;2012:18–28. Veeck J, Dahl E. Targeting the wnt pathway in cancer: the emerging role of dickkopf-3. Biochim Biophys Acta. 1825;2012:18–28.
11.
Zurück zum Zitat Sakaguchi M, Huh NH, Namba M. A novel tumor suppressor, reic/dkk-3 gene identified by our in vitro transformation model of normal human fibroblasts works as a potent therapeutic anti-tumor agent. Adv Exp Med Biol. 2011;720:209–15.CrossRefPubMed Sakaguchi M, Huh NH, Namba M. A novel tumor suppressor, reic/dkk-3 gene identified by our in vitro transformation model of normal human fibroblasts works as a potent therapeutic anti-tumor agent. Adv Exp Med Biol. 2011;720:209–15.CrossRefPubMed
12.
Zurück zum Zitat Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Canc J Int Canc. 2009;124:287–97.CrossRef Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Canc J Int Canc. 2009;124:287–97.CrossRef
13.
Zurück zum Zitat Freese JL, Pino D, Pleasure SJ. Wnt signaling in development and disease. Neurobiol Dis. 2010;38:148–53.CrossRefPubMed Freese JL, Pino D, Pleasure SJ. Wnt signaling in development and disease. Neurobiol Dis. 2010;38:148–53.CrossRefPubMed
14.
Zurück zum Zitat Baron R, Kneissel M. Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–92.CrossRefPubMed Baron R, Kneissel M. Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–92.CrossRefPubMed
15.
Zurück zum Zitat Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013;25:254–64.CrossRefPubMed Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013;25:254–64.CrossRefPubMed
Metadaten
Titel
Preliminary mechanism on the methylation modification of Dkk-1 and Dkk-3 in hepatocellular carcinoma
verfasst von
Libo Liang
He He
Ruixue Lv
Mei Zhang
Henjian Huang
Zhenmei An
Shuangqing Li
Publikationsdatum
01.02.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2750-y

Weitere Artikel der Ausgabe 2/2015

Tumor Biology 2/2015 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.